Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
840.33 x 1 842.52 x 1
Pre-market by (Cboe BZX)
837.57 -5.00 (-0.59%) 03/21/25 [NYSE]
840.33 x 1 842.52 x 1
Pre-market 842.27 +4.70 (+0.56%) 07:37 ET
Quote Overview for Fri, Mar 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
832.46
Day High
854.39
Open 839.03
Previous Close 837.57 837.57
Volume 3,168 3,168
Avg Vol 3,616,413 3,616,413
Stochastic %K 32.57% 32.57%
Weighted Alpha +5.31 +5.31
5-Day Change +15.57 (+1.89%) +15.57 (+1.89%)
52-Week Range 711.40 - 972.53 711.40 - 972.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 794,158,720
  • Shares Outstanding, K 948,170
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 12,899 M
  • EBITDA $ 14,666 M
  • 60-Month Beta 0.34
  • Price/Sales 17.74
  • Price/Cash Flow 59.19
  • Price/Book 56.05

Options Overview Details

View History
  • Implied Volatility 30.72% ( +1.35%)
  • Historical Volatility 29.13%
  • IV Percentile 48%
  • IV Rank 25.33%
  • IV High 55.08% on 08/05/24
  • IV Low 22.46% on 06/28/24
  • Put/Call Vol Ratio 0.79
  • Today's Volume 30,851
  • Volume Avg (30-Day) 37,399
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 286,205
  • Open Int (30-Day) 278,328

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 4.62
  • Number of Estimates 9
  • High Estimate 5.36
  • Low Estimate 4.27
  • Prior Year 2.58
  • Growth Rate Est. (year over year) +79.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
795.38 +5.65%
on 03/13/25
Period Open: 881.40
935.63 -10.19%
on 03/03/25
-41.07 (-4.66%)
since 02/24/25
3-Month
725.01 +15.91%
on 01/17/25
Period Open: 795.67
935.63 -10.19%
on 03/03/25
+44.66 (+5.61%)
since 12/24/24
52-Week
711.40 +18.12%
on 11/18/24
Period Open: 770.61
972.53 -13.59%
on 08/22/24
+69.72 (+9.05%)
since 03/22/24

Most Recent Stories

More News
Market Sell-Off: Can Buying These 3 "Safe" Stocks Today Set You Up for Life?

These fundamentally strong stocks remain safer picks, despite the heightened market volatility.

AVGO : 191.66 (+0.59%)
BRK-A : N/A (N/A)
BRK.TO : 39.08 (-1.34%)
LLY : 837.57 (-0.59%)
BRK-B : N/A (N/A)
J&J to Invest $55B in United States to Boost Manufacturing, R&D

J&J JNJ announced plans to invest more than $55 billion in the United States over the next four years to boost manufacturing, R&D and technology in the country.  This represents a 25% increase in investment compared...

JNJ : 163.63 (+0.37%)
LLY : 837.57 (-0.59%)
PFE : 26.28 (+0.34%)
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market

Abbvie made an all-time high after announcing an agreement that puts it in the weight loss market; but that just continues a general uptrend in ABBV stock

NVO : 76.86 (-2.45%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug market is expected to generate $12.8 billion in sales this year, and according...

VKTX : 28.95 (+2.12%)
NVO : 76.86 (-2.45%)
LLY : 837.57 (-0.59%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 163.63 (+0.37%)
MRK : 93.11 (-1.71%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has...

NVO : 76.86 (-2.45%)
LLY : 837.57 (-0.59%)
HLN : 10.28 (-1.06%)
GSK : 39.24 (-0.43%)
5 Reasons It's Not Too Late to Buy Eli Lilly Stock

Eli Lilly (NYSE: LLY) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.

LLY : 837.57 (-0.59%)
UNH : 516.85 (+1.09%)
3 Market-Beating Stocks to Target This Week

3 Market-Beating Stocks to Target This Week

GVA : 76.20 (-0.07%)
LLY : 837.57 (-0.59%)
HUBB : 338.36 (-0.24%)
Why Novo Nordisk Stock Outpaced the Market on Tuesday

Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the stock exchange Tuesday. The company was one of the rare enterprises seeing an increase...

NVO : 76.86 (-2.45%)
$SPX : 5,667.56 (+0.08%)
UBS : 32.74 (-0.76%)
LLY : 837.57 (-0.59%)
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry.AMGN Stock PerformanceImage Source: Zacks Investment ResearchAmgen’s stock has been rising consistently,...

NVO : 76.86 (-2.45%)
LLY : 837.57 (-0.59%)
ABBV : 210.01 (-0.92%)
AMGN : 316.04 (+0.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 875.33
2nd Resistance Point 862.88
1st Resistance Point 850.22
Last Price 840.33
1st Support Level 825.12
2nd Support Level 812.67
3rd Support Level 800.01

See More

52-Week High 972.53
Fibonacci 61.8% 872.78
Fibonacci 50% 841.97
Last Price 840.33
Fibonacci 38.2% 811.15
52-Week Low 711.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals